Clinical trials: Bone Diseases, Metabolic
Osteopenia
A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women
The primary objective of this study is to determine the safety and tolerability of AMG 167 following a single dose subcutaneous (SC) or intravenous (IV) administration in healthy men and postmenopausal women.
- Trial name
- NCT00902356
- Testing
- AMG 167
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Amgen
Infant, Small for Gestational Age
Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone
This non-interventional study for prospective follow up of a cohort of 220 subjects born small for gestational age (SGA) is planned for the purpose of finding out if normalisation of adult height is associated or not with…
- Trial name
- SGA (NCT01196156)
- Where
- 28 sites in Spain
- Volunteers
- 443 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Osteopenia, Osteoporosis
Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women
The primary objective of this clinical trial is to determine the effects of hesperidin on biochemical markers of bone in post-menopausal women.
- Trial name
- NCT00545116
- Testing
- Hesperidin
- Where
- Malaysia
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Osteoporosis
EVA: Evista Alendronate Comparison
The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures
- Trial name
- NCT00035971
- Testing
- raloxifene HCI and alendronate Na
- Where
- 86 sites in United States, Canada
- Sponsor
- Eli Lilly and Company
Osteoporosis
HORIZON-PFT: Pivotal Fracture Trial
HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause.
- Trial name
- NCT00049829
- Testing
- Zoledronic Acid
- Where
- 60 sites in United States, Germany
- Volunteers
- 7,700 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
CONFIRM EXTENSION - Long-term Follow-up Study of Patients Treated with AGN1 LOEP
The study is designed as a multi-center study within Europe in up to 60 patients treated with the AGN1 LOEP Kit in CONFIRM. This will be a non-randomized and non-blinded study.
- Trial name
- NCT04511364
- Testing
- Clinical imaging is performed during the 24 and 60 month follow-up visits
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- AgNovos Healthcare, LLC
Painful Osteoporotic Vertebral Compression Fractures (VCF)
The PRIORi-T Trial--Prospective Randomized Investigation of Radiofrequency Targeted Vertebral Augmentation
The objective of this post market clinical investigation is to evaluate the clinical effectiveness of a minimally invasive vertebral augmentation procedure, Radiofrequency-Targeted Vertebral Augmentation (RF-TVA) as compared to…
- Trial name
- PRIORi-T (NCT01480167)
- Testing
- Vertebral Augmentation (STABILIT), Non-operative Management
- Where
- 6 sites in United States
- Sponsor
- DFINE Inc.
Osteoporosis
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids
- Trial name
- NCT00799266
- Testing
- Zoledronic acid
- Where
- 12 sites in Australia, Canada and 4 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Postmenopausal Bone Loss
Effects of Arzoxifene on Bone Mass and the Uterus
The purposes of this study are to determine: The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. The effects of arzoxifene on the uterus (womb) in postmenopausal women.
- Trial name
- NCT00085956
- Testing
- Arzoxifene
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
X-Linked Hypophosphatemia
Registry for Patients With X-Linked Hypophosphatemia
This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH).
- Trial name
- NCT03193476
- Where
- 118 sites in Belgium, Bulgaria and 18 more
- Volunteers
- 1,489 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism
Clinical Evaluation of NeoPlex4 Assay and NeoPlex System
The purpose of this study is to assess the agreement of clinical performance between the proposed NeoPlex 4 assay and NeoPlex System and the comparator devices in clinical use in newborn screening programs for detection of T4…
- Conditions
- Adrenal Hyperplasia, Congenital, Congenital Hypothyroidism, Cystic Fibrosis
- Trial name
- NCT01488721
- Where
- 3 sites in United States
- Volunteers
- 7,462 people, healthy volunteers welcome
- Sponsor
- Luminex Corporation
Hypochondroplasia
Prospective Clinical Assessment Study in Children With Hypochondroplasia
This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).
- Trial name
- HCH (NCT06410976)
- Where
- 25 sites in United States, Australia and 8 more
- Volunteers
- 150 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Osteoporosis, Fracture
Develop and Validate Ultrasonic Device for Osteoporotic Fracture Risk Assessment
Study to demonstrate that the Bone UltraSonic Scanner (BUSS) can aid in detection of osteoporosis and predict prevalent osteoporotic fractures.
- Conditions
- Osteoporosis, Fracture, Aging
- Trial name
- BUSS03 (NCT01123421)
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- Artann Laboratories
X-Linked Hypophosphatemia
Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners
Through observation of patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) for up to 10 years, the study intends to collect data that allow achievement of the following objectives: 1.
- Trial name
- SUNFLOWER (NCT03745521)
- Testing
- no intervention
- Where
- Japan
- Volunteers
- 226 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Osteoporosis
A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo
The purpose of this randomized, double-blind, placebo-controlled study is to estimate the effect of oral ibandronate sodium (Boniva) taken once monthly versus placebo on bone quality and strength at the proximal femur at one year.
- Trial name
- NCT00148915
- Testing
- ibandronate
- Where
- 14 sites in United States
- Volunteers
- 98 people
- Sponsor
- Hoffmann-La Roche
Psoriatic Arthritis, Overweight or Obesity
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related…
- Trial name
- NCT06864026
- Testing
- Tirzepatide
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
Teriparatide Use in Hip Replaced Subjects
A pilot study on the use of Teriparatide in severe osteoporotic women with hip fracture and submitted to hip replacement The primary objective of this study is to obtain preliminary data, in a pilot group of postmenopausal women…
- Trial name
- NCT00191321
- Testing
- Teriparatide
- Where
- 11 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Postmenopausal Osteoporosis
Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis
This study is to evaluate the efficacy and safety of JMT103 in the treatment of postmenopausal women with osteoporosis.
- Trial name
- NCT05278338
- Testing
- JMT103, Denosumab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.
Age-Related Bone Loss, Bone Loss, Age Related
Radio-frequency Identification (RFID) Osteoporosis Pilot Study
This examines in-vivo microwave sensing to measure a radio- frequency signal propagating through the wrist and, based on this information, establish a correlation of measured parameters with the integral bone density.
- Trial name
- NCT03385941
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Neva Electromagnetics, LLC
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals